FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147804563> ?p ?o ?g. }

• W2147804563 endingPage "2719" @default.
• W2147804563 startingPage "2719" @default.
• W2147804563 abstract "Incidence of end-stage renal disease due to hypertension has increased in recent decades, but the optimal strategy for treatment of hypertension to prevent renal failure is unknown, especially among African Americans.To compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine), and a beta-blocker (metoprolol) on hypertensive renal disease progression.Interim analysis of a randomized, double-blind, 3 x 2 factorial trial conducted in 1094 African Americans aged 18 to 70 years with hypertensive renal disease (glomerular filtration rate [GFR] of 20-65 mL/min per 1.73 m(2)) enrolled between February 1995 and September 1998. This report compares the ramipril and amlodipine groups following discontinuation of the amlodipine intervention in September 2000.Participants were randomly assigned to receive amlodipine, 5 to 10 mg/d (n = 217), ramipril, 2.5 to 10 mg/d (n = 436), or metoprolol, 50 to 200 mg/d (n = 441), with other agents added to achieve 1 of 2 blood pressure goals.The primary outcome measure was the rate of change in GFR; the main secondary outcome was a composite index of the clinical end points of reduction in GFR of more than 50% or 25 mL/min per 1.73 m(2), end-stage renal disease, or death.Among participants with a urinary protein to creatinine ratio of >0.22 (corresponding approximately to proteinuria of more than 300 mg/d), the ramipril group had a 36% (2.02 [SE, 0.74] mL/min per 1.73 m(2)/y) slower mean decline in GFR over 3 years (P =.006) and a 48% reduced risk of the clinical end points vs the amlodipine group (95% confidence interval [CI], 20%-66%). In the entire cohort, there was no significant difference in mean GFR decline from baseline to 3 years between treatment groups (P =.38). However, compared with the amlodipine group, after adjustment for baseline covariates the ramipril group had a 38% reduced risk of clinical end points (95% CI, 13%-56%), a 36% slower mean decline in GFR after 3 months (P =.002), and less proteinuria (P<.001).Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." @default.
• W2147804563 created "2016-06-24" @default.
• W2147804563 creator A5000218151 @default.
• W2147804563 creator A5002919429 @default.
• W2147804563 creator A5005788616 @default.
• W2147804563 creator A5005815856 @default.
• W2147804563 creator A5008309890 @default.
• W2147804563 creator A5008859836 @default.
• W2147804563 creator A5010304127 @default.
• W2147804563 creator A5012514694 @default.
• W2147804563 creator A5012601437 @default.
• W2147804563 creator A5015118064 @default.
• W2147804563 creator A5015656712 @default.
• W2147804563 creator A5016452405 @default.
• W2147804563 creator A5019107767 @default.
• W2147804563 creator A5019975711 @default.
• W2147804563 creator A5023938163 @default.
• W2147804563 creator A5026464093 @default.
• W2147804563 creator A5028802380 @default.
• W2147804563 creator A5035142139 @default.
• W2147804563 creator A5035165984 @default.
• W2147804563 creator A5036452059 @default.
• W2147804563 creator A5038084939 @default.
• W2147804563 creator A5038114801 @default.
• W2147804563 creator A5040270613 @default.
• W2147804563 creator A5040913447 @default.
• W2147804563 creator A5044979451 @default.
• W2147804563 creator A5048680434 @default.
• W2147804563 creator A5050491175 @default.
• W2147804563 creator A5051133604 @default.
• W2147804563 creator A5053852808 @default.
• W2147804563 creator A5055479743 @default.
• W2147804563 creator A5058217417 @default.
• W2147804563 creator A5059580482 @default.
• W2147804563 creator A5060070231 @default.
• W2147804563 creator A5062500649 @default.
• W2147804563 creator A5063237643 @default.
• W2147804563 creator A5064188100 @default.
• W2147804563 creator A5070623236 @default.
• W2147804563 creator A5071880870 @default.
• W2147804563 creator A5072774542 @default.
• W2147804563 creator A5073800105 @default.
• W2147804563 creator A5083328490 @default.
• W2147804563 creator A5085801535 @default.
• W2147804563 creator A5086275701 @default.
• W2147804563 creator A5089047049 @default.
• W2147804563 creator A5091370096 @default.
• W2147804563 date "2001-06-06" @default.
• W2147804563 modified "2023-10-10" @default.
• W2147804563 title "Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>" @default.
• W2147804563 cites W150935824 @default.
• W2147804563 cites W1894131949 @default.
• W2147804563 cites W1970184528 @default.
• W2147804563 cites W1975184389 @default.
• W2147804563 cites W1980221786 @default.
• W2147804563 cites W1998509977 @default.
• W2147804563 cites W2003348418 @default.
• W2147804563 cites W2016400390 @default.
• W2147804563 cites W2042133882 @default.
• W2147804563 cites W2044758663 @default.
• W2147804563 cites W2047549364 @default.
• W2147804563 cites W2048051429 @default.
• W2147804563 cites W2049447899 @default.
• W2147804563 cites W2055696770 @default.
• W2147804563 cites W2059707463 @default.
• W2147804563 cites W2067023576 @default.
• W2147804563 cites W2075676627 @default.
• W2147804563 cites W2079365407 @default.
• W2147804563 cites W2087798038 @default.
• W2147804563 cites W2088172412 @default.
• W2147804563 cites W2090860909 @default.
• W2147804563 cites W2094727696 @default.
• W2147804563 cites W2098347923 @default.
• W2147804563 cites W2102979143 @default.
• W2147804563 cites W2108807575 @default.
• W2147804563 cites W2114634962 @default.
• W2147804563 cites W2138670606 @default.
• W2147804563 cites W2148748683 @default.
• W2147804563 cites W2153701973 @default.
• W2147804563 cites W2156663584 @default.
• W2147804563 cites W2260451204 @default.
• W2147804563 cites W2297753288 @default.
• W2147804563 cites W2312400976 @default.
• W2147804563 cites W2341854053 @default.
• W2147804563 cites W2418293006 @default.
• W2147804563 cites W2615684303 @default.
• W2147804563 cites W3156148333 @default.
• W2147804563 cites W2319268509 @default.
• W2147804563 cites W2606392786 @default.
• W2147804563 doi "https://doi.org/10.1001/jama.285.21.2719" @default.
• W2147804563 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11386927" @default.
• W2147804563 hasPublicationYear "2001" @default.
• W2147804563 type Work @default.
• W2147804563 sameAs 2147804563 @default.
• W2147804563 citedByCount "881" @default.
• W2147804563 countsByYear W21478045632012 @default.
• W2147804563 countsByYear W21478045632013 @default.
• W2147804563 countsByYear W21478045632014 @default.

• next